Among these, the C5a antibody vilobelimab and the small molecule drug avocapan have received FDA approval for the treatment of COVID-19 and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This evidence concerns the gene C5 and vasculitis.